research use only

Defactinib (VS-6063) FAK inhibitor

Name: Defactinib (VS-6063)
Brand: Selleck Chemicals
SKU: S7654
Availability: InStock
Rating: 5 (80 reviews)

Cat.No.S7654

Defactinib (VS-6063, PF-04554878) is a selective, orally active FAK inhibitor currently in Phase 2.

Chemical Structure

Molecular Weight: 510.49

Jump to Mechanism of Action Cell Culture & Working Concentration Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: Purity: 99.98%

99.98

Related Targets	EGFR VEGFR JAK PDGFR FGFR Src FLT FLT3 HER2 Bcr-Abl HIF BTK ALK Syk Hck VDA ANGPTL
Related Products	PF-562271 (VS-6062) PF-573228 VS-4718 (PND-1186) PF-562271 HCl PF-562271 Besylate TAE226 (NVP-TAE226) GSK2256098 PF-431396 Y15 Ifebemtinib (BI-853520) Conteltinib(CT-707) Narmafotinib Semen Ziziphi Spinosae Extract FAK Antibody [B11N6] FAK Antibody [J10N20] GSK215 Phospho-FAK (Tyr397) Antibody [G24K11] Defactinib hydrochloride Solanesol (Nonaisoprenol)

Cell Culture, Treatment & Working Concentration

Cell Lines	Assay Type	Incubation Time	Activity Description	PMID
HepG2	Function assay		reduced and retarded multicellular spheroid formation	29332411
Bel-7402	Function assay		reduced and retarded multicellular spheroid formation	29332411
PC3-mm2	Function assay		Treatment of PC3-mm2 cells with defactinib led to a time- and dose-dependent inhibition of FAK phosphorylation	26530902
BON	Cell viability assay	72 h	GI50=5.42 μM	25971297
GGP-1	Cell viability assay	72 h	GI50=4.90 μM	25971297
CM	Cell viability assay	72 h	GI50=1.77 μM	25971297
KB-3-1	qHTS assay		P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	31515284
Click to View More Cell Line Experimental Data

Chemical Information, Storage & Stability

Molecular Weight	510.49	Formula	C₂₀H₂₁F₃N₈O₃S	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	1073154-85-4	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	PF-04554878			Smiles	CNC(=O)C1=CC=C(C=C1)NC2=NC=C(C(=N2)NCC3=NC=CN=C3N(C)S(=O)(=O)C)C(F)(F)F

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (195.89 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 50%PEG300 2 5%Tween80 3 40%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	5.000mg/ml (9.79mM)	Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified DMSO stock solution to 500 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to make it clear; then continue to add 400 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	5.000mg/ml (9.79mM)	Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to make it clear; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	FAK ^[1]
In vitro	In taxane-sensitive (SKOV3ip1) and taxane-resistant (SKOV3-TR) cell lines, Defactinib (VS-6063) significantly inhibits pFAK (Tyr397) expression. The combination of this compound synergistically decreases proliferation and increases apoptosis in SKOV3ip1, SKOV3-TR, HeyA8 and HeyA8-MDR cells. ^[1] Its combination with Y15 also synergistically decreases viability, clonogenicity, and cell attachment in thyroid cancer cell lines. ^[2]
In vivo	In both PTX-sensitive and PTX-resistant models, Defactinib (VS-6063) (50 mg/kg p.o.) enhances tumor growth inhibition. ^[1]
References	[1] https://pubmed.ncbi.nlm.nih.gov/24062525/ [2] https://pubmed.ncbi.nlm.nih.gov/25277206/

Applications

Methods	Biomarkers	PMID
Western blot	HER2 pY1248 / FAK pY397 / AKT pS473 / p-ERK pIGF1R / IGF1R / E-cadherin / vimentin / ZEB-1	27638858
Immunofluorescence	pFAK (Tyr 397) / pYB-1 (Ser 102)	24062525
Growth inhibition assay	Cell viability	25971297